BCAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Bicara Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$17.47+0.69 (+4.11%)
Close on Oct 19, 2026
- Market cap
- $1.19B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
70M of 66M shares
Institutional holders
171
39 new, 11 sold out
Net institutional buying
4M
In Q2 2026
Insider trades, 12 months
1 buys · 57 sales
Net sold $5.11M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| RA Capital Management, L.P. | 7,279,739 | 11.50% | 13D (active) amendment | Feb 26, 2026 |
| Ryan Wilder | 5,425,000 | 8.30% | 13G (passive) amendment | Mar 31, 2026 |
| Raymond Debbane | 5,216,969 | 9.60% | 13G (passive) amendment | Jun 30, 2025 |
| Deep Track Biotechnology Master Fund, Ltd. | 4,062,500 | 6.21% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 3,536,271 | 5.40% | 13G (passive) | Jun 30, 2026 |
| Janus Henderson Group PLC | 3,339,218 | 5.10% | 13G (passive) | Mar 31, 2026 |
| James G. Coulter | 3,010,425 | 5.50% | 13D (active) | Sep 16, 2024 |
| Vestal Point Capital, LP | 2,768,975 | 5.10% | 13G (passive) | Mar 31, 2025 |
| FMR LLC | 2,756,217 | 5.10% | 13G (passive) | Jul 10, 2025 |
| Deep Track Capital, LP | 2,750,000 | 5.02% | 13G (passive) | Feb 5, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BCAX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 7,255,993 | 10.97% | $215.43M | – | 1.87% |
| T. Rowe Price Investment Management, Inc. | 6,338,487 | 9.58% | $188.19K | −267,293 | 0.12% |
| Siren, L.L.C. | 5,602,970 | 8.47% | $166.35M | −200,000 | 3.37% |
| Vestal Point Capital, LP | 5,250,000 | 7.93% | $155.87M | −175,000 | 3.64% |
| Deep Track Capital, LP | 4,100,000 | 6.20% | $121.73M | +37,500 | 1.77% |
| BlackRock, Inc. | 3,848,090 | 5.82% | $114.25M | +1,004,383 | 0.00% |
| Jupiter Topco LLC | 3,171,015 | 4.79% | $93.96M | New | 0.04% |
| Red Tree Management, LLC | 3,163,517 | 4.78% | $93.92M | −6,992 | 63.77% |
| Tpg Gp A, LLC | 3,010,425 | 4.55% | $89.38M | – | 1.79% |
| Vanguard Capital Management LLC | 2,216,639 | 3.35% | $65.81M | +442,419 | 0.00% |
| State Street Corp | 2,048,920 | 3.10% | $60.83M | +629,532 | 0.00% |
| Franklin Resources Inc | 1,951,892 | 2.95% | $57.95M | +330,249 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 1,904,248 | 2.88% | $56.54K | +528,050 | 0.01% |
| FMR LLC | 1,893,070 | 2.86% | $56.21M | −207,859 | 0.00% |
| Omega Fund Management, LLC | 1,822,150 | 2.75% | $54.10M | −570,000 | 29.14% |
| Geode Capital Management, LLC | 1,162,635 | 1.76% | $34.53M | +331,729 | 0.00% |
| JPMorgan Chase & Co | 1,015,965 | 1.54% | $29.81M | +838,557 | 0.00% |
| Jones Hill Capital LP | 892,621 | 1.35% | $26.50M | −367,515 | 5.63% |
| Acorn Capital Advisors, LLC | 643,381 | 0.97% | $19.10M | −1 | 5.21% |
| Aisling Capital Management LP | 568,919 | 0.86% | $16.89M | – | 3.58% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 171 | 70M | 100.0% | 39 / 67 | 39 / 11 | 11M | 6M |
| Q1 2026 | 145 | 69M | 100.0% | 29 / 57 | 40 / 21 | 17M | 3M |
| Q4 2025 | 140 | 57M | 86.5% | 44 / 45 | 35 / 17 | 13M | 6M |
| Q3 2025 | 114 | 50M | 75.9% | 25 / 42 | 25 / 17 | 3M | 4M |
| Q2 2025 | 106 | 51M | 77.3% | 33 / 43 | 16 / 19 | 13M | 10M |
| Q1 2025 | 93 | 49M | 73.5% | 28 / 26 | 19 / 18 | 7M | 6M |
| Q4 2024 | 84 | 47M | 70.6% | 39 / 23 | 7 / 24 | 14M | 3M |
| Q3 2024 | 69 | 36M | 55.0% | 69 / 0 | 0 / 0 | 36M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of BCAX | Value | % of fund | As of |
|---|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock Fund, Inc. | 2,179,330 | 3.29% | $64.70M | 0.70% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,676,653 | 2.53% | $49.78M | 0.00% | Jun 30, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 1,170,492 | 1.77% | $34.75M | 0.69% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,149,801 | 1.74% | $34.14M | 0.04% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,096,543 | 1.66% | $32.56M | 0.30% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 944,900 | 1.43% | $20.55M | 0.39% | May 31, 2026 |
| Franklin Small Cap Growth Fund | 623,692 | 0.94% | $16.90M | 0.68% | Jul 31, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 612,100 | 0.93% | $18.17M | 0.19% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 604,729 | 0.91% | $17.95M | 0.17% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 591,014 | 0.89% | $17.55M | 0.15% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 491,079 | 0.74% | $14.58M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 483,715 | 0.73% | $13.11M | 0.04% | Jul 31, 2026 |
| Franklin Biotechnology Discovery Fund | 474,899 | 0.72% | $12.87M | 1.11% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 356,291 | 0.54% | $10.58M | 0.07% | Jun 30, 2026 |
| iShares Biotechnology ETF | 264,967 | 0.40% | $7.87M | 0.09% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ryan Cohlhepp | President, COO & Interim CEO, Director | 199,141 | 0.30% | Sep 10, 2026 |
| Claire Mazumdar | Chief Executive Officer, Director | 372,152 | 0.56% | Aug 12, 2026 |
| Jennifer Larson | Chief Financial Officer | – | – | Aug 14, 2026 |
| Ivan Hyep | Chief Financial Officer | 129,855 | 0.20% | Aug 12, 2026 |
| William Schelman | Chief Medical Officer | – | – | May 12, 2026 |
| David Raben | Chief Medical Officer | 60,786 | 0.09% | Apr 28, 2026 |
| Lara Meisner | Chief Legal Officer | 0 | – | Feb 4, 2026 |
| Christy J. Oliger | Director | – | – | Jul 29, 2026 |
| Jeremy Bender | Director | – | – | Jul 29, 2026 |
| Rajeev M. Shah | Director, 10% owner | – | – | Jun 10, 2026 |
| Kate Haviland | Director | 7,437 | 0.01% | Jun 10, 2026 |
| Michael Powell | Director | – | – | Jun 10, 2026 |
| Christopher Bowden | Director | – | – | Jun 10, 2026 |
| Jake Simson | Director | – | – | Jun 10, 2026 |
| Scott M. Robertson | Director | – | – | Jun 10, 2026 |
| Kiran Mazumdar-Shaw | Director | 6,297,854 | 9.52% | Jun 10, 2026 |
| Capital Healthcare Fund LP RA | Director | – | – | Jun 10, 2026 |
| Ra Capital Management, L.P. | Director, 10% owner | 4,603,418 | 6.96% | Jun 10, 2026 |
| Peter Kolchinsky | Director, 10% owner | – | – | Jun 10, 2026 |
| RA Capital Nexus Fund III, L.P. | Director | 2,622,898 | 3.96% | Jun 10, 2026 |
| Nils Lonberg | Director | 29,991 | 0.05% | Jun 10, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ryan Cohlhepp President, COO & Interim CEO, Director | Sep 8, 2026 | Option exercise | +17,500 | $3.79 | $66.33K | 199,141 |
| Ryan Cohlhepp President, COO & Interim CEO, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −14,058 | $22.77 | $320.10K | 185,083 |
| Ryan Cohlhepp President, COO & Interim CEO, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −3,442 | $23.43 | $80.65K | 181,641 |
| Ryan Cohlhepp President and COO, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −18,750 | $27.98 | $524.63K | 181,641 |
| Ryan Cohlhepp President and COO, Director | Aug 10, 2026 | Option exercise | +18,750 | $3.79 | $71.06K | 200,391 |
| Ivan Hyep Chief Financial Officer | Aug 10, 2026 | Sale(10b5-1 plan) | −12,500 | $27.97 | $349.63K | 129,855 |
| Ivan Hyep Chief Financial Officer | Aug 10, 2026 | Option exercise | +12,500 | $3.79 | $47.38K | 142,355 |
| Claire Mazumdar Chief Executive Officer, Director | Aug 10, 2026 | Option exercise | +10,000 | $3.79 | $37.90K | 372,152 |
| Claire Mazumdar Chief Executive Officer, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −10,000 | $27.98 | $279.80K | 362,152 |
| Claire Mazumdar Chief Executive Officer, Director | Jul 10, 2026 | Sale(10b5-1 plan) | −28 | $29.68 | $831 | 362,152 |
| Claire Mazumdar Chief Executive Officer, Director | Jul 10, 2026 | Sale(10b5-1 plan) | −9,972 | $28.42 | $283.40K | 362,180 |
| Claire Mazumdar Chief Executive Officer, Director | Jul 10, 2026 | Option exercise | +10,000 | $3.79 | $37.90K | 372,152 |
| Ryan Cohlhepp President and COO, Director | Jul 9, 2026 | Sale(10b5-1 plan) | −536 | $29.00 | $15.54K | 181,641 |
| Ivan Hyep Chief Financial Officer | Jul 8, 2026 | Sale(10b5-1 plan) | −4,413 | $29.82 | $131.60K | 130,685 |
| Ivan Hyep Chief Financial Officer | Jul 8, 2026 | Sale(10b5-1 plan) | −22,757 | $28.60 | $650.85K | 135,098 |
| Ivan Hyep Chief Financial Officer | Jul 8, 2026 | Option exercise | +12,500 | $3.79 | $47.38K | 157,855 |
| Ivan Hyep Chief Financial Officer | Jul 8, 2026 | Sale(10b5-1 plan) | −830 | $30.31 | $25.16K | 129,855 |
| Ryan Cohlhepp President and COO, Director | Jul 8, 2026 | Sale(10b5-1 plan) | −4,306 | $29.80 | $128.32K | 183,252 |
| Ryan Cohlhepp President and COO, Director | Jul 8, 2026 | Sale(10b5-1 plan) | −1,075 | $30.35 | $32.63K | 182,177 |
| Ryan Cohlhepp President and COO, Director | Jul 8, 2026 | Sale(10b5-1 plan) | −22,833 | $28.76 | $656.68K | 187,558 |
| Ryan Cohlhepp President and COO, Director | Jul 8, 2026 | Option exercise | +18,750 | $3.79 | $71.06K | 210,391 |
| Ivan Hyep Chief Financial Officer | May 21, 2026 | Sale(10b5-1 plan) | −9,200 | $20.42 | $187.86K | 145,355 |
| Ivan Hyep Chief Financial Officer | May 21, 2026 | Option exercise | +9,200 | $3.79 | $34.87K | 154,555 |
| Claire Mazumdar Chief Executive Officer, Director | May 18, 2026 | Sale(10b5-1 plan) | −2,978 | $20.35 | $60.60K | 362,152 |
| Claire Mazumdar Chief Executive Officer, Director | May 18, 2026 | Option exercise | +15,000 | $3.79 | $56.85K | 377,152 |
| Claire Mazumdar Chief Executive Officer, Director | May 18, 2026 | Sale(10b5-1 plan) | −12,022 | $19.96 | $239.96K | 365,130 |
| Ryan Cohlhepp President and COO, Director | May 15, 2026 | Sale(10b5-1 plan) | −4,500 | $20.29 | $91.31K | 191,641 |
| Ryan Cohlhepp President and COO, Director | May 15, 2026 | Sale(10b5-1 plan) | −8,000 | $20.29 | $162.32K | 196,141 |
| Ryan Cohlhepp President and COO, Director | May 15, 2026 | Option exercise | +8,000 | $3.79 | $30.32K | 204,141 |
| David Raben Chief Medical Officer | Apr 27, 2026 | Option exercise | +5,500 | $3.79 | $20.85K | 60,786 |
| David Raben Chief Medical Officer | Apr 27, 2026 | Sale(10b5-1 plan) | −5,500 | $22.88 | $125.84K | 55,286 |
| Ivan Hyep Chief Financial Officer | Apr 21, 2026 | Option exercise | +9,200 | $3.79 | $34.87K | 154,555 |
| Ivan Hyep Chief Financial Officer | Apr 21, 2026 | Sale(10b5-1 plan) | −9,200 | $23.00 | $211.60K | 145,355 |
| Claire Mazumdar Chief Executive Officer, Director | Apr 20, 2026 | Option exercise | +15,000 | $3.79 | $56.85K | 377,152 |
| Claire Mazumdar Chief Executive Officer, Director | Apr 20, 2026 | Sale(10b5-1 plan) | −15,000 | $23.61 | $354.15K | 362,152 |
| Claire Mazumdar Chief Executive Officer, Director | Apr 16, 2026 | Option exercise | +7,080 | $5.45 | $38.59K | 362,152 |
| Claire Mazumdar Chief Executive Officer, Director | Apr 16, 2026 | Option exercise | +7,454 | $3.79 | $28.25K | 355,072 |
| Claire Mazumdar Chief Executive Officer, Director | Apr 16, 2026 | Option exercise | +8,226 | $4.44 | $36.52K | 347,618 |
| Ryan Cohlhepp President and COO, Director | Apr 15, 2026 | Option exercise | +8,000 | $3.79 | $30.32K | 208,641 |
| Ryan Cohlhepp President and COO, Director | Apr 15, 2026 | Sale(10b5-1 plan) | −8,000 | $23.01 | $184.08K | 200,641 |
| Ryan Cohlhepp President and COO, Director | Apr 15, 2026 | Sale(10b5-1 plan) | −4,500 | $23.01 | $103.55K | 196,141 |
| David Raben Chief Medical Officer | Mar 25, 2026 | Option exercise | +5,500 | $3.79 | $20.85K | 60,786 |
| David Raben Chief Medical Officer | Mar 25, 2026 | Sale(10b5-1 plan) | −5,500 | $18.95 | $104.23K | 55,286 |
| Ivan Hyep Chief Financial Officer | Mar 23, 2026 | Sale(10b5-1 plan) | −9,200 | $18.52 | $170.38K | 145,355 |
| Ivan Hyep Chief Financial Officer | Mar 23, 2026 | Option exercise | +9,200 | $3.79 | $34.87K | 154,555 |
| Claire Mazumdar Chief Executive Officer, Director | Mar 20, 2026 | Option exercise | +1,596 | $3.79 | $6.05K | 340,988 |
| Claire Mazumdar Chief Executive Officer, Director | Mar 20, 2026 | Sale(10b5-1 plan) | −1,596 | $18.95 | $30.24K | 339,392 |
| Claire Mazumdar Chief Executive Officer, Director | Mar 19, 2026 | Option exercise | +6,905 | $3.79 | $26.17K | 346,297 |
| Claire Mazumdar Chief Executive Officer, Director | Mar 19, 2026 | Sale(10b5-1 plan) | −6,905 | $18.78 | $129.68K | 339,392 |
| Claire Mazumdar Chief Executive Officer, Director | Mar 18, 2026 | Option exercise | +6,499 | $3.79 | $24.63K | 345,891 |
| Claire Mazumdar Chief Executive Officer, Director | Mar 18, 2026 | Sale(10b5-1 plan) | −6,499 | $18.84 | $122.44K | 339,392 |
| Ryan Cohlhepp President and COO, Director | Mar 16, 2026 | Option exercise | +8,000 | $3.79 | $30.32K | 213,141 |
| Ryan Cohlhepp President and COO, Director | Mar 16, 2026 | Sale(10b5-1 plan) | −4,500 | $19.66 | $88.47K | 200,641 |
| Ryan Cohlhepp President and COO, Director | Mar 16, 2026 | Sale(10b5-1 plan) | −8,000 | $19.66 | $157.28K | 205,141 |
| Claire Mazumdar Chief Executive Officer, Director | Mar 9, 2026 | Option exercise | +36,766 | $3.79 | $139.34K | 376,158 |
| Claire Mazumdar Chief Executive Officer, Director | Mar 9, 2026 | Sale(10b5-1 plan) | −36,766 | $19.17 | $704.80K | 339,392 |
| Claire Mazumdar Chief Executive Officer, Director | Mar 6, 2026 | Option exercise | +3,817 | $3.79 | $14.47K | 343,209 |
| Claire Mazumdar Chief Executive Officer, Director | Mar 6, 2026 | Sale(10b5-1 plan) | −3,817 | $18.75 | $71.57K | 339,392 |
| Claire Mazumdar Chief Executive Officer, Director | Mar 5, 2026 | Option exercise | +1,786 | $3.79 | $6.77K | 341,178 |
| Claire Mazumdar Chief Executive Officer, Director | Mar 5, 2026 | Sale(10b5-1 plan) | −1,786 | $18.74 | $33.47K | 339,392 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Ryan Cohlhepp Officer, Director | Sep 8, 2026 | 17,500 | $396.20K | Sep 8, 2026 | Exercise of Stock Option |
| Ivan Hyep Officer | Sep 8, 2026 | 12,500 | $283.00K | Sep 8, 2026 | Exercise of stock options |
| Ivan Hyep Officer | Aug 10, 2026 | 12,500 | $347.88K | Aug 10, 2026 | Exercise of stock options |
| Ryan Cohlhepp Officer, Director | Aug 10, 2026 | 18,750 | $521.81K | Aug 10, 2026 | Exercise of Stock Option |
| Claire Mazumdar Officer, Director | Aug 10, 2026 | 10,000 | $278.30K | Aug 10, 2026 | Exercise of stock options |
| Claire Mazumdar Officer, Director | Jul 10, 2026 | 10,000 | $296.80K | Jul 10, 2026 | Exercise of stock options |
| Raben David Officer | Jul 8, 2026 | 50,000 | $1.43M | Jul 8, 2026 | Stock Option Exercise |
| Ryan Cohlhepp Officer, Director | Jul 8, 2026 | 28,750 | $869.69K | Jul 8, 2026 | Exercise of Stock Option |
| Ivan Hyep Officer | Jul 8, 2026 | 28,000 | $847.00K | Jul 8, 2026 | Exercise of stock options |
| Meisner Lara Officer | Jul 7, 2026 | 1,000 | $29.77K | Jul 7, 2026 | Stock Option Exercise |
| Raben David Officer | Jun 25, 2026 | 50,000 | $1.32M | Jun 25, 2026 | Stock Option Exercise |
| Lara Meisner Former Chief Legal Officer | Jun 1, 2026 | 71,390 | $1.47M | Jun 1, 2026 | Exercise of Stock Options |
| David Raben Officer | May 26, 2026 | 5,500 | $120.01K | May 26, 2026 | Exercise of Stock Options |
| Ivan Hyep Officer | May 21, 2026 | 9,200 | $187.88K | May 21, 2026 | Exercise of stock options |
| Claire Mazumdar Officer, Director | May 18, 2026 | 15,000 | $313.80K | May 18, 2026 | Exercise of stock options |